Scopus BioPharma (SCPS) Ratios
Scopus BioPharma Ratios
SCPS's free cash flow for Q2 2023 was $-1.01M. For the 2023 fiscal year, SCPS's free cash flow was increased by $0.00 and operating cash flow was $-1.01M. See a summary of the company’s cash flow.
| Ratios | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.05 | 1.96 | 0.52 | 0.90 | 0.96 |
| Quick Ratio | 0.05 | 1.96 | 0.52 | 0.90 | 0.96 |
| Cash Ratio | 0.02 | 1.90 | 0.48 | 0.04 | 0.01 |
| Solvency Ratio | -1.56 | -6.65 | -3.04 | -3.15 | -3.80 |
| Operating Cash Flow Ratio | -1.09 | -2.74 | -0.66 | -2.48 | -5.42 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -1.11 | 0.00 | 0.00 |
| Net Current Asset Value | $ -7.06M | $ 4.01M | $ -1.83M | $ -86.52K | $ -5.33K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 1.16 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | -1.25 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 5.05 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.06 | 2.04 | -1.08 | -9.31 | -24.90 |
| Debt Service Coverage Ratio | 0.00 | -34.79 | -3.63 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | -35.67 | -14.38 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.04 | 0.22 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.01 | 0.30 | -0.04 | 0.01 | 0.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 99.10% | 102.87% | 106.50% | 100.00% | 100.00% |
| EBT Per EBIT | 100.00% | 97.53% | 106.96% | 100.00% | 100.00% |
| Return on Assets (ROA) | -2959.69% | -338.65% | -586.04% | -348.58% | -517.17% |
| Return on Equity (ROE) | 176.86% | -690.19% | 631.75% | 3246.42% | 12879.53% |
| Return on Capital Employed (ROCE) | 165.88% | -687.86% | 554.59% | 3246.42% | 12879.53% |
| Return on Invested Capital (ROIC) | 164.39% | -687.86% | -2244.37% | 3246.42% | 12879.53% |
| Return on Tangible Assets | -2959.69% | -338.65% | -586.04% | -348.58% | -517.17% |
| Earnings Yield | -561.61% | -98.00% | -5.83% | -3.03% | -0.77% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.39 | -0.66 | -0.19 | -0.14 | -0.05 |
| Free Cash Flow Per Share | -0.39 | -0.66 | -0.19 | -0.14 | -0.05 |
| Dividend Paid and CapEx Coverage Ratio | -5236.23 | -5715.18 | 0.00 | -498.80 | 0.00 |
| Capital Expenditure Coverage Ratio | -5236.23 | -5715.18 | 0.00 | -498.80 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | -1.11 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -393.19% | -40.39% | -1.27% | -2.40% | -0.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.18 | -1.02 | -17.14 | -32.96 | -129.24 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.31 | 7.04 | -108.29 | -1069.96 | -16645.91 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.25 | -2.48 | -78.53 | -41.73 | -118.63 |
| Price-to-Operating Cash Flow Ratio | -0.25 | -2.48 | -78.53 | -41.81 | -118.63 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.01 | -0.04 | -0.11 | 0.00 |
| Enterprise Value Multiple | -0.17 | -0.78 | -19.57 | -32.95 | -129.24 |
| Enterprise Value | 1.94M | 20.35M | 198.76M | 88.62M | 88.65M |
| EV to EBITDA | -0.17 | -0.78 | -19.57 | -32.95 | -129.24 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.24 | -1.78 | -78.71 | -41.71 | -118.63 |
| EV to Operating Cash Flow | -0.24 | -1.78 | -78.71 | -41.79 | -118.63 |
| Tangible Book Value Per Share | -0.33 | 0.23 | -0.14 | -0.01 | -0.00 |
| Shareholders’ Equity Per Share | -0.31 | 0.23 | -0.14 | -0.01 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | -0.03 | -0.07 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.55 | -1.61 | -0.87 | -0.18 | -0.05 |
| Tax Burden | 0.99 | 1.03 | 1.07 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.03 | 1.07 | 1.00 | 0.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.69 | 0.42 | 2.40 | 0.79 | 1.09 |
Currency in USD